# CABATEN (NCT04400474)

> Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

No report yet. It can be ordered.

- Drugs tested: cabozantinib plus atezolizumab
- Indication: advanced and progressive neoplasms of the endocrine system

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04400474
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- Conditions: Neuroendocrine Tumor; Anaplastic Thyroid Cancer; Adenocarcinoma; Pheochromocytoma; Paraganglioma
- Interventions: Cabozantinib 40 mg
- Enrollment: 93
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on CABATEN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 16 posts on X
- 2 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cabaten-nct04400474

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04400474", "email": "<work email>"}; the inbox owner confirms by the emailed link.